Brief: Kane Biotech Makes First Commercial Sale Of Revyve™ Antimicrobial Wound Gel To ProgenaCare Global
27/06/2024 13:55
June 27 (Reuters) - Kane Biotech Inc KNE.V :
* KANE BIOTECH MAKES FIRST COMMERCIAL SALE OF REVYVE™
ANTIMICROBIAL WOUND GEL TO PROGENACARE GLOBAL
Source text for Eikon: ID:nGNX5Flpqs
Further company coverage: KNE.V
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kane Biotech
See all newsBrief: Kane Biotech Announces FDA 510(K) Clearance For Revyve® Antimicrobial Skin And Wound Cleanser
Brief: Kane Biotech Restarts Commercial Activities And Strengthens North American Management
Brief: Kane Biotech Completes U.S. FDA 510(K) Submission For Revyve Antimicrobial Wound Cleanser
Brief: Kane Biotech Announces Second Quarter 2025 Financial Results
Brief: Kane Biotech provides further corporate update